Skip to main content

Table 3 Next-year results for the monthly and bimonthly follow-up groups

From: Effectiveness of monthly and bimonthly follow-up of patients with well-controlled type 2 diabetes: a propensity score matched cohort study

 

Monthly follow-up (n = 693)

Bimonthly follow-up (n = 693)

Baseline, mean ± SD or n (%)

Next year, mean ± SD or n (%)

Baseline, mean ± SD or n (%)

Next year, mean ± SD or n (%)

Bionthly - monthly difference (95% CI)a

HbA1c (%)

6.0 ± 0.5

6.1 ± 0.6

6.0 ± 0.5

6.1 ± 0.5

−0.02 (−0.07 to 0.03)

Systolic blood pressure (mmHg)

129.6 ± 15.6

129.4 ± 14.7

129.7 ± 15.9

129.8 ± 15.3

0.26 (−1.32 to 1.83)

Diastolic blood pressure (mmHg)

74.8 ± 9.6

74.4 ± 9.4

74.7 ± 9.8

74.4 ± 9.4

0.11 (− 0.87 to 1.09)

LDL (mg/dl)

118.0 ± 27.1

115.9 ± 25.5

119.2 ± 28.8

116.5 ± 26.8

−0.61 (−3.06 to 1.83)

HDL (mg/dl)

59.3 ± 14.7

59.7 ± 15.2

59.2 ± 15.0

59.6 ± 15.3

0.01 (−0.79 to 0.81)

TG (mg/dl)

121.2 ± 66.8

125.9 ± 77.1

123.2 ± 69.9

124.3 ± 67.8

−3.6 (−10.28 to 3.08)

BMI

23.4 ± 3.0

23.4 ± 3.0

23.4 ± 3.2

23.4 ± 3.2

−0.06 (−0.13 to 0.02)

Current smoker (%)

63 (9.1)

65 (9.4)

71 (10.3)

70 (10.1)

−0.43 (−2.11 to 1.24)

Regular exercise (%)

334 (48.2)

356 (51.5)

348 (50.2)

365 (52.8)

−0.73 (−5.46 to 4.00)b

Sleep well (%)

595 (85.9)

588 (85.3)

598 (86.3)

590 (85.5)

−0.43 (−4.16 to 3.29)

Daily alcohol intake (%)

141 (20.4)

142 (20.5)

150 (21.7)

149 (21.5)

−0.29 (−2.45 to 1.87)

Annual cost (JPY)

 

161,294 ± 151,826

 

96,292 ± 179,272

− 6500.17 (− 8253.53 to − 4746.80)§

  1. SD Standard deviation, CI Confidence interval, HbA1c Hemoglobin A1c, BMI Body mass index, LDL Low-density lipoprotein, HDL High-density lipoprotein, TG Triacylglycerol
  2. aThe differences in follow-up measurements were corrected for baseline measurement except annual cost
  3. bNot within equivalence range